PRECIGEN, INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
PRECIGEN, INC. (PGEN) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $9.57 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-08-13
- PRECIGEN, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $9.57M, a 4.13% decline year-over-year.
- PRECIGEN, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $7.15M, a 12.03% decline year-over-year.
- PRECIGEN, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $7.81M, a 5.45% decline year-over-year.
- PRECIGEN, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $7.67M, a 17.17% decline year-over-year.
- PRECIGEN, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $33.59M, a 9.12% decline from fiscal 2016.
- PRECIGEN, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $36.96M, a 11.75% decline from fiscal 2015.
- PRECIGEN, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $41.88M, a 264.77% increase from fiscal 2014.
- PRECIGEN, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $11.48M, a 6900.61% increase from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-06-30 | $9.57M 10-Q · filed 2018-08-13 | $16.72M 10-Q · filed 2018-08-13 | $24.53M derived: sum of 3 quarters · filed 2018-08-13 | $32.20M derived: sum of 4 quarters · filed 2018-08-13 |
| 2018-03-31 | $7.15M 10-Q/A · filed 2018-08-13 | $14.96M derived: sum of 2 quarters · filed 2018-08-13 | $22.63M derived: sum of 3 quarters · filed 2018-08-13 | $32.61M derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-12-31 | $7.81M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $15.48M derived: sum of 2 quarters · filed 2018-03-01 | $25.46M derived: sum of 3 quarters · filed 2018-08-13 | $33.59M 10-K · filed 2018-03-01 |
| 2017-09-30 | $7.67M 10-Q · filed 2017-11-09 | $17.65M derived: sum of 2 quarters · filed 2018-08-13 | $25.78M 10-Q · filed 2017-11-09 | $34.04M derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-06-30 | $9.98M 10-Q · filed 2018-08-13 | $18.11M 10-Q · filed 2018-08-13 | $26.37M derived: sum of 3 quarters · filed 2018-08-13 | $35.63M derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-03-31 | $8.13M 10-Q/A · filed 2018-08-13 | $16.39M derived: sum of 2 quarters · filed 2018-08-13 | $25.65M derived: sum of 3 quarters · filed 2018-08-13 | $36.53M derived: sum of 4 quarters · filed 2018-08-13 |
| 2016-12-31 | $8.26M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $17.52M derived: sum of 2 quarters · filed 2018-03-01 | $28.40M derived: sum of 3 quarters · filed 2018-03-01 | $36.96M 10-K · filed 2018-03-01 |
| 2016-09-30 | $9.26M 10-Q · filed 2017-11-09 | $20.14M derived: sum of 2 quarters · filed 2017-11-09 | $28.70M 10-Q · filed 2017-11-09 | $37.93M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $10.88M 10-Q · filed 2017-08-09 | $19.44M 10-Q · filed 2017-08-09 | $28.67M derived: sum of 3 quarters · filed 2018-03-01 | $38.12M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $8.55M 10-Q · filed 2017-05-10 | $17.79M derived: sum of 2 quarters · filed 2018-03-01 | $27.23M derived: sum of 3 quarters · filed 2018-03-01 | $41.50M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $9.23M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $18.68M derived: sum of 2 quarters · filed 2018-03-01 | $32.95M derived: sum of 3 quarters · filed 2018-03-01 | $41.88M 10-K · filed 2018-03-01 |
| 2015-09-30 | $9.45M 10-Q · filed 2016-11-09 | $23.71M derived: sum of 2 quarters · filed 2016-11-09 | $32.65M 10-Q · filed 2016-11-09 | $40.00M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $14.27M 10-Q · filed 2016-08-09 | $23.20M 10-Q · filed 2016-08-09 | $30.56M derived: sum of 3 quarters · filed 2017-03-01 | $34.67M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $8.93M 10-Q · filed 2016-05-10 | $16.29M derived: sum of 2 quarters · filed 2017-03-01 | $20.41M derived: sum of 3 quarters · filed 2017-03-01 | $20.41M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $7.36M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $11.47M derived: sum of 2 quarters · filed 2017-03-01 | $11.48M derived: sum of 3 quarters · filed 2017-03-01 | $11.48M 10-K · filed 2017-03-01 |
| 2014-09-30 | $4.12M 10-Q · filed 2015-11-09 | $4.12M derived: sum of 2 quarters · filed 2015-11-09 | $4.12M 10-Q · filed 2015-11-09 | $4.29M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $9.00K 10-Q · filed 2015-08-10 | $9.00K 10-Q · filed 2015-08-10 | $173.00K derived: sum of 3 quarters · filed 2016-02-29 | $173.00K derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $0.00 10-Q · filed 2015-05-11 | $164.00K derived: sum of 2 quarters · filed 2016-02-29 | $164.00K derived: sum of 3 quarters · filed 2016-02-29 | |
| 2013-12-31 | $164.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $164.00K derived: sum of 2 quarters · filed 2016-02-29 | $164.00K 10-K · filed 2016-02-29 | |
| 2013-09-30 | $0.00 10-Q · filed 2014-11-13 | $0.00 10-Q · filed 2014-11-13 | ||
| 2012-12-31 | $0.00 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |